Sunday, December 17, 2017
Tailwinds' Take: getting an abstract at ASCO is a coup for ITUS as it demonstrates the progress being made on their C-Chek platform. Data from the abstract will be available on January 22nd, three days before the conference starts,...
TORONTO, Dec. 01, 2017 (GLOBE NEWSWIRE) – 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or “3DS“) is pleased to announce an upsize of its previously announced non-brokered private placement and the results of its Annual General Meeting of...
Great presentation by Dyadic's CEO lays out the upside thesis for investing in DYAI. The downside, with cash much higher than the current share price, is very limited in our opinion.
In a widely anticipated move, President Trump abandoned the Paris Climate Agreement this week. Widely hailed as a landmark agreement that would set in place the structure to slow climate change, Trump believed it was overly restrictive on the...
The Factory System Will Help the Stem Cell Industry Standardize, Integrate, and Automate Unit Operations Stem cell therapies hold extraordinary potential to revolutionize human medicine. Indeed, the global market for cell-based therapies is expected to surpass $20 billion by 2025,...
Tailwinds' Take: Earthstone is poised for a big 2017. These numbers show the strength ESTE had coming into this year, but guidance on the call is the key. Back to you with more on that sometime soon. THE WOODLANDS, TX...
NAMUR, Belgium, Nov. 3, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced its collaboration with Hvidovre Hospital, University of Copenhagen, Denmark in a prospective clinical study...
NEW YORK, NY -- (Marketwired) -- 11/21/16 -- iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced the issue of a new Canadian patent in the company's iBioModulator™ thermostable immunomodulator...
Tailwinds' Take: Impressive revenue growth, clearly demonstrating the strong position CYRX has in a rapidly growing marketplace. Phase III customers will translate into significant revenue as their drugs progress from the lab to approved usage. IRVINE, Calif., Nov. 14, 2016 /PRNewswire/...
NEW YORK, NY -- (Marketwired) -- 11/10/16 -- iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced completion of expanded product development capacity of its subsidiary, iBio CMO LLC, for...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address